Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells.
about
Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches.Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation.Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.
P2860
Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Anti-leukemic activity of dasatinib in both p53
@nl
Anti-leukemic activity of dasa ...... 53(mutated) B malignant cells.
@en
type
label
Anti-leukemic activity of dasatinib in both p53
@nl
Anti-leukemic activity of dasa ...... 53(mutated) B malignant cells.
@en
prefLabel
Anti-leukemic activity of dasatinib in both p53
@nl
Anti-leukemic activity of dasa ...... 53(mutated) B malignant cells.
@en
P2093
P2860
P1476
Anti-leukemic activity of dasa ...... 53(mutated) B malignant cells.
@en
P2093
Claudio Celeghini
Federica Corallini
Marco Rabusin
Raffaella Bosco
Rebecca Voltan
P2860
P2888
P304
P356
10.1007/S10637-010-9564-6
P577
2010-10-16T00:00:00Z